The first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs; gefitinib, erlotinib) had a major impact on the treatment of non-small cell lung cancer and established the importance of early and universal genotyping for this disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.